世界の腫瘍溶解性ウイルス免疫治療市場2020年-2030年:種類別(単純ヘルペスウイルス、ワクシニアウイルス、アデノウイルス、レオウイルス、その他)、投与経路別、用途別

◆英語タイトル:Oncolytic Virus Immunotherapy Market (Type: Herpes Simplex Virus, Vaccinia Virus, Adenovirus, Reovirus, Others; Route of Administration: Intratumoral and Intravenous; and Application: Melanoma, Non-small Cell Lung Cancer [NSCLC], Pancreatic Cancer, Breast Cancer, and Others) – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2020-2030
◆商品コード:TMR21FB024
◆発行会社(リサーチ会社):Transparency Market Research
◆発行日:2020年10月1日
◆ページ数:182
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single User(1名様閲覧)USD5,795 ⇒換算¥660,630見積依頼/購入/質問フォーム
Site Licence(同一拠点内共有可)USD8,795 ⇒換算¥1,002,630見積依頼/購入/質問フォーム
Enterprisewide Licence(複数拠点内共有可)USD11,795 ⇒換算¥1,344,630見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はTransparency Market Research社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Transparency Market Research社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

Transparency Market Research社の本市場調査レポートでは、世界の腫瘍溶解性ウイルス免疫治療市場について調査・分析し、序論、仮定/調査手法、エグゼクティブサマリー、市場概要、キーインサイト、種類別(単純ヘルペスウイルス、ワクシニアウイルス、アデノウイルス、レオウイルス、その他)分析、投与経路別分析、用途別分析、地域別(北米、ヨーロッパ、アジア太平洋、その他)分析、競争状況を掲載しています。
・序論
・仮定/調査手法
・エグゼクティブサマリー
・市場概要
・キーインサイト
・世界の腫瘍溶解性ウイルス免疫治療市場規模:種類別(単純ヘルペスウイルス、ワクシニアウイルス、アデノウイルス、レオウイルス、その他)
・世界の腫瘍溶解性ウイルス免疫治療市場規模:投与経路別
・世界の腫瘍溶解性ウイルス免疫治療市場規模:用途別
・世界の腫瘍溶解性ウイルス免疫治療市場規模:地域別(北米、ヨーロッパ、アジア太平洋、その他)
・競争状況
【レポートの概要】

Oncolytic Virus Immunotherapy Market – Scope of the Report

TMR’s report on the global oncolytic virus immunotherapy market studies past as well as current growth trends and opportunities to gain valuable insights of these indicators of the market during the forecast period from 2020 to 2030. The report provides revenue of the global oncolytic virus immunotherapy market for the period 2018–2030, considering 2019 as the base year and 2030 as the forecast year. The report also provides the compound annual growth rate (CAGR) for the global oncolytic virus immunotherapy market during the forecast period.

The report has been prepared after primary and secondary researches. Primary research involves bulk of research efforts, wherein analysts carried out interviews with industry leaders and opinion makers. Secondary research involves referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the global oncolytic virus immunotherapy market.

Secondary research also includes Internet sources, statistical data from government agencies, websites, company presentations, sales data, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various phenomenon in the global oncolytic virus immunotherapy market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Furthermore, the report sheds light on the changing competitive dynamics in the global oncolytic virus immunotherapy market. These indices serve as valuable tools for existing market players as well as for entities interested in entering the global oncolytic virus immunotherapy market.

The report delves into the competition landscape of the global oncolytic virus immunotherapy market. Key players operating in the global oncolytic virus immunotherapy market have been identified, and each one of these has been profiled for distinguishing business attributes. Company overview, financial standings, recent developments, and SWOT are some of the attributes of players in the global oncolytic virus immunotherapy market that have been profiled in this report.

Key Questions Answered in Oncolytic Virus Immunotherapy Market Report

What is the scope of growth for product companies in the global oncolytic virus immunotherapy market?
What will be the Y-o-Y growth of the global oncolytic virus immunotherapy market between 2020 and 2030?
What is the influence of changing trends in technologies on the global oncolytic virus immunotherapy market?
Will North America continue to be the most profitable market for oncolytic virus immunotherapy?
Which factors are anticipated to hamper the global oncolytic virus immunotherapy market during the forecast period?
Which are the leading companies in the global oncolytic virus immunotherapy market?
Research Methodology

A unique methodology has been utilized by TMR to conduct comprehensive research on the growth of the global oncolytic virus immunotherapy market and arrive at conclusions on its growth prospects. This research methodology is a combination of primary and secondary research, which helps analysts warrant the accuracy and reliability of the drawn conclusions.

Secondary research sources referred to by analysts during the production of the global oncolytic virus immunotherapy market report include statistics from company annual reports, SEC filings, company websites, investor presentations, regulatory databases, government publications, and industry white papers. Analysts have also interviewed senior managers, product portfolio managers, CEOs, VPs, and market intelligence managers, who contributed to the production of TMR’s study on the oncolytic virus immunotherapy market as primary methods.

These primary research respondents have provided exclusive information during interviews, which serves as a validation from the oncolytic virus immunotherapy market leaders. Access to an extensive internal repository and external proprietary databases enabled this report to address specific details and questions about the global oncolytic virus immunotherapy market with accuracy. The study also uses the top-down approach to assess the revenue of each segment and the bottom-up approach to counter-validate them. This has helped in reaching TMR’s estimates on future prospects of the global oncolytic virus immunotherapy more reliably and accurately

【レポートの目次】

1. Preface

1.1. Market Definition and Scope

1.2. Market Segmentation

1.3. Key Research Objectives

1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Oncolytic Virus Immunotherapy Market

4. Market Overview

4.1. Introduction

4.1.1. Type Definition

4.1.2. Industry Evolution / Developments

4.2. Overview

4.3. Market Dynamics

4.3.1. Drivers

4.3.2. Restraints

4.3.3. Opportunities

4.4. Global Oncolytic Virus Immunotherapy Market Analysis and Forecast, 2018–2030

5. Key Insights

5.1. COVID-19 Pandemic Impact on Industry (Value Chain and Short / Mid / Long Term Impact)

5.2. Pipeline Analysis

5.3. Key Industry Developments

5.4. Features of oncolytic viruses

6. Global Oncolytic Virus Immunotherapy Market Analysis and Forecast, by Type

6.1. Introduction & Definition

6.2. Key Findings / Developments

6.3. Global Oncolytic Virus Immunotherapy Market Value Forecast, by Type, 2018–2030

6.3.1. Herpes Simplex Virus

6.3.2. Vaccinia Virus

6.3.3. Adenovirus

6.3.4. Reovirus

6.3.5. Others

6.4. Global Oncolytic Virus Immunotherapy Market Attractiveness Analysis, by Type

7. Global Oncolytic Virus Immunotherapy Market Analysis and Forecast, by Route of Administration

7.1. Introduction & Definition

7.2. Key Findings / Developments

7.3. Global Oncolytic Virus Immunotherapy Market Value Forecast, by Route of Administration, 2018–2030

7.3.1. Intratumoral

7.3.2. Intravenous

7.4. Global Oncolytic Virus Immunotherapy Market Attractiveness Analysis, by Route of Administration

8. Global Oncolytic Virus Immunotherapy Market Analysis and Forecast, by Application

8.1. Introduction & Definition

8.2. Key Findings / Developments

8.3. Global Oncolytic Virus Immunotherapy Market Value Forecast, by Application, 2018–2030

8.3.1. Melanoma

8.3.2. Non-small Cell Lung Cancer (NSCLC)

8.3.3. Pancreatic Cancer

8.3.4. Breast Cancer

8.3.5. Others

8.4. Global Oncolytic Virus Immunotherapy Market Attractiveness Analysis, by Application

9. Global Oncolytic Virus Immunotherapy Market Analysis and Forecast, by Region

9.1. Key Findings

9.2. Global Oncolytic Virus Immunotherapy Market Value Forecast, by Region

9.2.1. North America

9.2.2. Europe

9.2.3. Asia Pacific

9.2.4. Rest of World

9.3. Global Oncolytic Virus Immunotherapy Market Attractiveness Analysis, by Country/Region

10. North America Oncolytic Virus Immunotherapy Market Analysis and Forecast

10.1. Introduction

10.1.1. Key Findings

10.2. North America Oncolytic Virus Immunotherapy Market Value Forecast, by Type, 2018–2030

10.2.1. Herpes Simplex Virus

10.2.2. Vaccinia Virus

10.2.3. Adenovirus

10.2.4. Reovirus

10.2.5. Others

10.3. North America Oncolytic Virus Immunotherapy Market Value Forecast, by Route of Administration, 2018–2030

10.3.1. Intratumoral

10.3.2. Intravenous

10.4. North America Oncolytic Virus Immunotherapy Market Value Forecast, by Application, 2018–2030

10.4.1. Melanoma

10.4.2. Non-small Cell Lung Cancer (NSCLC)

10.4.3. Pancreatic Cancer

10.4.4. Breast Cancer

10.4.5. Others

10.5. North America Oncolytic Virus Immunotherapy Market Value Forecast, by Country, 2018–2030

10.5.1. U.S.

10.5.2. Canada

10.6. North America Oncolytic Virus Immunotherapy Market Attractiveness Analysis

10.6.1. By Type

10.6.2. By Route of Administration

10.6.3. By Application

10.6.4. By Country

11. Europe Oncolytic Virus Immunotherapy Market Analysis and Forecast

11.1. Introduction

11.1.1. Key Findings

11.2. Europe Oncolytic Virus Immunotherapy Market Value Forecast, by Type, 2018–2030

11.2.1. Herpes Simplex Virus

11.2.2. Vaccinia Virus

11.2.3. Adenovirus

11.2.4. Reovirus

11.2.5. Others

11.3. Europe Oncolytic Virus Immunotherapy Market Value Forecast, by Route of Administration, 2018–2030

11.3.1. Intratumoral

11.3.2. Intravenous

11.4. Europe Oncolytic Virus Immunotherapy Market Value Forecast, by Application, 2018–2030

11.4.1. Melanoma

11.4.2. Non-small Cell Lung Cancer (NSCLC)

11.4.3. Pancreatic Cancer

11.4.4. Breast Cancer

11.4.5. Others

11.5. Europe Oncolytic Virus Immunotherapy Market Value Forecast, by Country/Sub-region, 2018–2030

11.5.1. Germany

11.5.2. U.K.

11.5.3. France

11.5.4. Spain

11.5.5. Italy

11.5.6. Rest of Europe

11.6. Europe Oncolytic Virus Immunotherapy Market Attractiveness Analysis

11.6.1. By Type

11.6.2. By Route of Administration

11.6.3. By Application

11.6.4. By Country/Sub-region

12. Asia Pacific Oncolytic Virus Immunotherapy Market Analysis and Forecast

12.1. Introduction

12.1.1. Key Findings

12.2. Asia Pacific Oncolytic Virus Immunotherapy Market Value Forecast, by Type, 2018–2030

12.2.1. Herpes Simplex Virus

12.2.2. Vaccinia Virus

12.2.3. Adenovirus

12.2.4. Reovirus

12.2.5. Others

12.3. Asia Pacific Oncolytic Virus Immunotherapy Market Value Forecast, by Route of Administration, 2018–2030

12.3.1. Intratumoral

12.3.2. Intravenous

12.4. Asia Pacific Oncolytic Virus Immunotherapy Market Value Forecast, by Application, 2018–2030

12.4.1. Melanoma

12.4.2. Non-small Cell Lung Cancer (NSCLC)

12.4.3. Pancreatic Cancer

12.4.4. Breast Cancer

12.4.5. Others

12.5. Asia Pacific Oncolytic Virus Immunotherapy Market Value Forecast, by Country/Sub-region, 2018–2030

12.5.1. China

12.5.2. Japan

12.5.3. India

12.5.4. Australia & New Zealand

12.5.5. Rest of Asia Pacific

12.6. Asia Pacific Oncolytic Virus Immunotherapy Market Attractiveness Analysis

12.6.1. By Type

12.6.2. By Route of Administration

12.6.3. By Application

12.6.4. By Country/Sub-region

13. Rest of World Oncolytic Virus Immunotherapy Market Analysis and Forecast

13.1. Introduction

13.1.1. Key Findings

13.2. Rest of World Oncolytic Virus Immunotherapy Market Value Forecast, by Type, 2018–2030

13.2.1. Herpes Simplex Virus

13.2.2. Vaccinia Virus

13.2.3. Adenovirus

13.2.4. Reovirus

13.2.5. Others

13.3. Rest of World Oncolytic Virus Immunotherapy Market Value Forecast, by Route of Administration, 2018–2030

13.3.1. Intratumoral

13.3.2. Intravenous

13.4. Rest of World Oncolytic Virus Immunotherapy Market Value Forecast, by Application, 2018–2030

13.4.1. Melanoma

13.4.2. Non-small Cell Lung Cancer (NSCLC)

13.4.3. Pancreatic Cancer

13.4.4. Breast Cancer

13.4.5. Others

13.5. Rest of World Oncolytic Virus Immunotherapy Market Value Forecast, by Country/Sub-region, 2018–2030

13.5.1. Brazil

13.5.2. Mexico

13.5.3. Rest of Latin America

13.6. Rest of World Oncolytic Virus Immunotherapy Market Attractiveness Analysis

13.6.1. By Type

13.6.2. By Route of Administration

13.6.3. By Application

13.6.4. By Country/Sub-region

14. Competition Landscape

14.1. Market Player – Competition Matrix (By Tier and Size of companies)

14.2. Market Share Analysis/Ranking, by Company, 2019

14.3. Company Profiles

14.3.1. Amgen Inc.

14.3.1.1. Company Overview

14.3.1.2. Company Financials

14.3.1.3. Growth Strategies

14.3.1.4. SWOT Analysis

14.3.2. Merck & Co., Inc. (Viralytics Limited)

14.3.2.1. Company Overview

14.3.2.2. Company Financials

14.3.2.3. Growth Strategies

14.3.2.4. SWOT Analysis

14.3.3. Shanghai Sunway Biotech Co., Ltd

14.3.3.1. Company Overview

14.3.3.2. Growth Strategies

14.3.3.3. SWOT Analysis

14.3.4. TILT Biotherapeutics

14.3.4.1. Company Overview

14.3.4.2. Growth Strategies

14.3.4.3. SWOT Analysis

14.3.5. Oncorus, Inc.

14.3.5.1. Company Overview

14.3.5.2. Growth Strategies

14.3.5.3. SWOT Analysis

14.3.6. Replimune Group, Inc.

14.3.6.1. Company Overview

14.3.6.2. Company Financials

14.3.6.3. Growth Strategies

14.3.6.4. SWOT Analysis

14.3.7. Oncolys BioPharma, Inc.

14.3.7.1. Company Overview

14.3.7.2. Company Financials

14.3.7.3. Growth Strategies

14.3.7.4. SWOT Analysis

14.3.8. Sorrento Therapeutics, Inc.

14.3.8.1. Company Overview

14.3.8.2. Company Financials

14.3.8.3. Growth Strategies

14.3.8.4. SWOT Analysis

14.3.9. Oncolytics Biotech, Inc.

14.3.9.1. Company Overview

14.3.9.2. Company Financials

14.3.9.3. Growth Strategies

14.3.9.4. SWOT Analysis

14.3.10. SillaJen, Inc.

14.3.10.1. Company Overview

14.3.10.2. Growth Strategies

14.3.10.3. SWOT Analysis

List of Table

Table 01: Global Oncolytic Virus Immunotherapy Market Value (US$ Mn) Forecast, by Type, 2018–2030

Table 02: Global Oncolytic Virus Immunotherapy Market Value (US$ Mn) Forecast, by Route of Administration, 2018–2030

Table 03: Global Oncolytic Virus Immunotherapy Market Value (US$ Mn) Forecast, by Type, 2018–2030

Table 04: Global Oncolytic Virus Immunotherapy Market Value (US$ Mn) Forecast, by Region, 2018–2030

Table 05: North America Oncolytic Virus Immunotherapy Market Revenue (US$ Mn) Forecast, by Country, 2018–2030

Table 06: North America Oncolytic Virus Immunotherapy Market Revenue (US$ Mn) Forecast, by Type, 2018–2030

Table 07: North America Oncolytic Virus Immunotherapy Market Revenue (US$ Mn) Forecast, by Route of Administration, 2018–2030

Table 08: North America Oncolytic Virus Immunotherapy Market Revenue (US$ Mn) Forecast, by Application, 2018–2030

Table 09: Europe Oncolytic Virus Immunotherapy Market Revenue (US$ Mn) Forecast, by Country/Sub-region, 2018–2030

Table 10: Europe Oncolytic Virus Immunotherapy Market Revenue (US$ Mn) Forecast, by Type, 2018–2030

Table 11: Europe Oncolytic Virus Immunotherapy Market Revenue (US$ Mn) Forecast, by Route of Administration, 2018–2030

Table 12: Europe Oncolytic Virus Immunotherapy Market Revenue (US$ Mn) Forecast, by Application, 2018–2030

Table 13: Asia Pacific Oncolytic Virus Immunotherapy Market Revenue (US$ Mn) Forecast, by Country/Sub-region, 2018–2030

Table 14: Asia Pacific Oncolytic Virus Immunotherapy Market Revenue (US$ Mn) Forecast, by Type, 2018–2030

Table 15: Asia Pacific Oncolytic Virus Immunotherapy Market Revenue (US$ Mn) Forecast, by Route of Administration, 2018–2030

Table 16: Asia Pacific Oncolytic Virus Immunotherapy Market Revenue (US$ Mn) Forecast, by Application, 2018–2030

Table 17: Rest of World Oncolytic Virus Immunotherapy Market Revenue (US$ Mn) Forecast, by Type, 2018–2030

Table 18: Rest of World Oncolytic Virus Immunotherapy Market Revenue (US$ Mn) Forecast, by Route of Administration, 2018–2030

Table 19: Rest of World Oncolytic Virus Immunotherapy Market Revenue (US$ Mn) Forecast, by Application, 2018–2030

List of Figure

Figure 01: Global Oncolytic Virus Immunotherapy Market Value (US$ Mn) Forecast, 2018–2030

Figure 02: Global Oncolytic Virus Immunotherapy Market Value Share, by Type, 2019

Figure 03: Global Oncolytic Virus Immunotherapy Market Value Share, by Route of Administration, 2019

Figure 04: Global Oncolytic Virus Immunotherapy Market Value Share, by Application, 2019

Figure 05: Global Oncolytic Virus Immunotherapy Market Value Share, by Region, 2019

Figure 06: Global Oncolytic Virus Immunotherapy Market Value Share Analysis, by Type, 2019 and 2030

Figure 07: Global Oncolytic Virus Immunotherapy Market Attractiveness Analysis, by Type, 2020–2030

Figure 08: Global Oncolytic Virus Immunotherapy Market Revenue (US$ Mn), by Herpes Simplex Virus, 2018–2030

Figure 09: Global Oncolytic Virus Immunotherapy Market Revenue (US$ Mn), by Vaccinia Virus, 2018–2030

Figure 10: Global Oncolytic Virus Immunotherapy Market Revenue (US$ Mn), by Adenovirus, 2018–2030

Figure 11: Global Oncolytic Virus Immunotherapy Market Revenue (US$ Mn), by Reovirus, 2018–2030

Figure 12: Global Oncolytic Virus Immunotherapy Market Revenue (US$ Mn), by Others, 2018–2030

Figure 13: Global Oncolytic Virus Immunotherapy Market Value Share Analysis, by Route of Administration, 2019 and 2030

Figure 14: Global Oncolytic Virus Immunotherapy Market Attractiveness Analysis, by Route of Administration, 2020–2030

Figure 15: Global Oncolytic Virus Immunotherapy Market Revenue (US$ Mn), by Intratumoral, 2018–2030

Figure 16: Global Oncolytic Virus Immunotherapy Market Revenue (US$ Mn), by Intravenous, 2018–2030

Figure 17: Global Oncolytic Virus Immunotherapy Market Value Share Analysis, by Application, 2019 and 2030

Figure 18: Global Oncolytic Virus Immunotherapy Market Attractiveness Analysis, by Application, 2020–2030

Figure 19: Global Oncolytic Virus Immunotherapy Market Revenue (US$ Mn), by Melanoma, 2018–2030

Figure 20: Global Oncolytic Virus Immunotherapy Market Revenue (US$ Mn), by Non-small Cell Lung Cancer (NSCLC), 2018–2030

Figure 21: Global Oncolytic Virus Immunotherapy Market Revenue (US$ Mn), by Pancreatic Cancer, 2018–2030

Figure 22: Global Oncolytic Virus Immunotherapy Market Revenue (US$ Mn), by Breast Cancer, 2018–2030

Figure 23: Global Oncolytic Virus Immunotherapy Market Revenue (US$ Mn), by Others, 2018–2030

Figure 24: Global Oncolytic Virus Immunotherapy Market Value Share Analysis, by Region, 2019 and 2030

Figure 25: Global Oncolytic Virus Immunotherapy Market Attractiveness Analysis, by Region

Figure 26: North America Oncolytic Virus Immunotherapy Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018–2030

Figure 27: North America Oncolytic Virus Immunotherapy Market Value Share (%), by Country, 2019 and 2030

Figure 28: North America Oncolytic Virus Immunotherapy Market Attractiveness Analysis, by Country, 2020–2030

Figure 29: North America Oncolytic Virus Immunotherapy Market Value Share (%), by Type, 2019 and 2030

Figure 30: North America Oncolytic Virus Immunotherapy Market Attractiveness Analysis, by Type, 2020–2030

Figure 31: North America Oncolytic Virus Immunotherapy Market Value Share (%), by Route of Administration, 2019 and 2030

Figure 32: North America Oncolytic Virus Immunotherapy Market Attractiveness Analysis, by Route of Administration, 2020–2030

Figure 33: North America Oncolytic Virus Immunotherapy Market Value Share (%), by Application, 2019 and 2030

Figure 34: North America Oncolytic Virus Immunotherapy Market Attractiveness Analysis, by Application, 2020–2030

Figure 35: Europe Oncolytic Virus Immunotherapy Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018–2030

Figure 36: Europe Oncolytic Virus Immunotherapy Market Value Share (%), by Country/Sub-region, 2019 and 2030

Figure 37: Europe Oncolytic Virus Immunotherapy Market Attractiveness Analysis, by Country/Sub-region, 2020–2030

Figure 38: Europe Oncolytic Virus Immunotherapy Market Value Share (%), by Type, 2019 and 2030

Figure 39: Europe Oncolytic Virus Immunotherapy Market Attractiveness Analysis, by Type, 2020–2030

Figure 40: Europe Oncolytic Virus Immunotherapy Market Value Share (%), by Route of Administration, 2019 and 2030

Figure 41: Europe Oncolytic Virus Immunotherapy Market Attractiveness Analysis, by Route of Administration, 2020–2030

Figure 42: Europe Oncolytic Virus Immunotherapy Market Value Share (%), by Application, 2019 and 2030

Figure 43: Europe Oncolytic Virus Immunotherapy Market Attractiveness Analysis, by Application, 2020–2030

Figure 44: Asia Pacific Oncolytic Virus Immunotherapy Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018–2030

Figure 45: Asia Pacific Oncolytic Virus Immunotherapy Market Value Share (%), by Country/Sub-region, 2019 and 2030

Figure 46: Asia Pacific Oncolytic Virus Immunotherapy Market Attractiveness Analysis, by Country/Sub-region, 2020–2030

Figure 47: Asia Pacific Oncolytic Virus Immunotherapy Market Value Share (%), by Type, 2019 and 2030

Figure 48: Asia Pacific Oncolytic Virus Immunotherapy Market Attractiveness Analysis, by Type, 2020–2030

Figure 49: Asia Pacific Oncolytic Virus Immunotherapy Market Value Share (%), by Route of Administration, 2019 and 2030

Figure 50: Asia Pacific Oncolytic Virus Immunotherapy Market Attractiveness Analysis, by Route of Administration, 2020–2030

Figure 51: Asia Pacific Oncolytic Virus Immunotherapy Market Value Share (%), by Application, 2019 and 2030

Figure 52: Asia Pacific Oncolytic Virus Immunotherapy Market Attractiveness Analysis, by Application, 2020–2030

Figure 53: Rest of World Oncolytic Virus Immunotherapy Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018–2030

Figure 54: Rest of World Oncolytic Virus Immunotherapy Market Value Share (%), by Type, 2021 and 2030

Figure 55: Rest of World Oncolytic Virus Immunotherapy Market Attractiveness Analysis, by Type, 2022–2030

Figure 56: Rest of World Oncolytic Virus Immunotherapy Market Value Share (%), by Route of Administration, 2021 and 2030

Figure 57: Rest of World Oncolytic Virus Immunotherapy Market Attractiveness Analysis, by Route of Administration, 2022–2030

Figure 58: Rest of World Oncolytic Virus Immunotherapy Market Value Share (%), by Application, 2021 and 2030

Figure 59: Rest of World Oncolytic Virus Immunotherapy Market Attractiveness Analysis, by Application, 2022–2030

Figure 60: Amgen, Inc. Revenue (US$ Mn) and Y-o-Y Growth (%), 2016-2019

Figure 61: Amgen, Inc. Breakdown of Net Sales (%), by Region/Country, 2019

Figure 62: Amgen, Inc. R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2016-2019

Figure 63: Merck & Co., Inc. Revenue (US$ Mn) and Y-o-Y Growth (%), 2017-2019

Figure 64: Merck & Co., Inc. Breakdown of Net Sales (%), by Region/Country, 2019

Figure 65: Merck & Co., Inc. Breakdown of Net Sales (%), by Business Segment, 2019

Figure 66: Merck & Co., Inc. R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2017-2019

Figure 67: Replimune Group, Inc. Total Operating Expenses (US$ Mn) and Y-o-Y Growth (%), 2018-2020

Figure 68: Replimune Group, Inc. R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2018-2019

Figure 69: Oncolys BioPharma, Inc. Revenue (US$ Mn) and Y-o-Y Growth (%), 2017-2019

Figure 70: Oncolys BioPharma, Inc. Breakdown of Net Sales (%), by Region/Country, 2019

Figure 71: Sorrento Therapeutics, Inc. Revenue (US$ Mn) and Y-o-Y Growth (%), 2016-2019

Figure 72: Sorrento Therapeutics, Inc. Breakdown of Net Sales (%), by Business Segment, 2019

Figure 73: Sorrento Therapeutics, Inc. R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2016-2019

Figure 74: Oncolytics Biotech, Inc. Total assets (US$ Mn) and Y-o-Y Growth (%), 2017-2019

Figure 75: Oncolytics Biotech, Inc. R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2017-2019

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[世界の腫瘍溶解性ウイルス免疫治療市場2020年-2030年:種類別(単純ヘルペスウイルス、ワクシニアウイルス、アデノウイルス、レオウイルス、その他)、投与経路別、用途別]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆